GILDGilead Sciences, Inc.
$125.59
$0.28
(0.22%)
Closed $125.59
$0.94
(0.75%)
After Hours
EarningsAug 6
Mkt Cap$156.28B
Vol5.22M
Fundamentals
Mkt Cap
$156.28B
Volume
-
52W High
$157.29
52W Low
$104.46
PE Ratio
17.09
Avg. Volume
6.68M
EPS (Annual)
$6.78
Rev/Employee
$1,732,235.29
Earnings
Aug 06
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Zacks
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight...
Business Wire
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
Zacks
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Zacks
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV...
Business Wire
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gileads Trodelvy (sacituzumab govitecan-hziy) in combination with KEYTRUDA (pembrolizumab...
Business Wire
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?
Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now...
Yahoo! Finance: News
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia...
Business Wire
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
Zacks
<
1
2
...
>